Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01955707 · ClinicalTrials.gov registry record · Phase 2
Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
A Phase 2 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 2
- Development phase
- 161
- Enrollment target
NCT01955707 is a Phase 2 study that has completed, run by Biogen. The registered enrollment target is 161 participants.
The verdict
NCT01955707, a Phase 2 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 161 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine whether one 300 mg dose of intravenous (IV) natalizumab reduces change in infarct volume from Baseline to Day 5 on magnetic resonance imaging (MRI) in participants with acute ischemic stroke when given at ≤6 hours or at \>6 to ≤9 hours from when they were last known normal (LKN). The secondary objectives of this study in this study population are as follows: to assess the efficacy of natalizumab on change in infarct volume from Baseline to Day 30; to assess efficacy of natalizumab on change in infarct volume from 24 hours to Day 5 and Day 30; to assess the efficacy of natalizumab on clinical measures of stroke outcome; to assess the safety of natalizumab in participants with acute ischemic stroke.
Interventions
- DRUG Placebo
- DRUG natalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01955707
The ClinicalTrials.gov registry entry for NCT01955707 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01955707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01955707 about?
NCT01955707 is a clinical study titled "Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke". The primary objective of the study is to determine whether one 300 mg dose of intravenous (IV) natalizumab reduces change in infarct volume from Baseline to Day 5 on magnetic resonance imaging (MRI) in participants with acute ischemic stroke when given at ≤6 hours or at \>6 to ≤9 hours from when the...
What is the current status of trial NCT01955707?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 161 participants. The study started on 2014-01. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01955707?
The interventions under investigation include: Placebo (DRUG), natalizumab (DRUG).
Who is sponsoring clinical trial NCT01955707?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.